DIKUL - logo
E-resources
Peer reviewed Open access
  • Update on the Feasibility a...
    Toesca, Antonio; Invento, Alessandra; Massari, Giulia; Girardi, Antonia; Peradze, Nickolas; Lissidini, Germana; Sangalli, Claudia; Maisonneuve, Patrick; Manconi, Andrea; Gottardi, Alessandra; Baker, Jennifer L.; Bottiglieri, Luca; Naninato, Paola; Farante, Gabriel; Magnoni, Francesca; De Scalzi, Alessandra; Corso, Giovanni; Colleoni, Marco; De Lorenzi, Francesca; Sacchini, Virgilio; Galimberti, Viviana; Intra, Mattia; Rietjens, Mario; Veronesi, Paolo

    Annals of surgical oncology, 10/2019, Volume: 26, Issue: 10
    Journal Article

    Background Robotic nipple-sparing mastectomy (RNSM) may allow for more precise anatomic dissection and improved cosmetic outcomes over conventional open nipple-sparing mastectomy; however, data regarding the feasibility and safety of the procedure are limited. Objective The aim of this study was to present and discuss perioperative surgical outcomes and early oncologic follow-up data on consecutive patients undergoing RNSM from June 2014 to January 2019. Methods Patients underwent RNSM and immediate robotic breast reconstruction through an axillary incision at a single institution. Perioperative data, complications at 3 months postoperatively, pathological data, and adjuvant therapies were recorded. Local recurrence-free, disease-free, and overall survival were analyzed. Results Overall, 73 women underwent 94 RNSM procedures. Indications were invasive breast cancer in 39 patients, ductal carcinoma in situ in 17 patients, and BRCA mutation in 17 patients. Mean surgery time was 3 h and 32 min. One-step reconstruction with implant occurred in 89.4% of procedures. The rate of complications requiring reoperation was 4.3%, and the rate of flap or nipple necrosis was 1.1%. Median follow-up was 19 months (range 3.1–44.8). No local recurrences occurred. Overall survival at 12, 24, or 60 months was 98% (95% confidence interval 86–100%). Conclusion We observed a low complication rate in 94 consecutive RNSM procedures, demonstrating the procedure is technically feasible and safe. We found no early local failures at 19 months follow-up. Long-term follow-up is needed to confirm oncologic safety. Future clinical trials to study the advantages and disadvantages of RNSM are warranted.